• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Ocular Therapeutix touts Medicare reimbursement win

May 29, 2019 By Fink Densford

Ocular Therapeutix logo

Ocular Therapeutix (NSDQ:OCUL) said today that the Centers for Medicare and Medicaid Services approved a transitional pass-through payment status and established a new reimbursement C-code for its Dextenza device.

The Bedford, Mass.-based company’s Dextenza device is designed to deliver drugs for up to 30 days following treatment in a physician’s office. Ocular Therapeutix is positioning its product as a way to eliminate the current standard of care for post-surgical pain – topical steroid eye drops.

Ocular Therapeutix said that the C-code it received is scheduled to become effective on July 1, 2019. The receipt of the C-code will allow for CMS to reimburse for Dextenza until the group approves a J-Code, which has already been preliminarily recommended and if granted, would become effective January 1, 2020.

“We are pleased to receive pass-through payment status and assignment of a new C-code for Dextenza which physicians and their practices may use for reimbursement of the product. With sample product available and insertion training sessions already underway, the receipt of the C-code is another important step in the commercial launch of Dextenza,” prez & CEO Antony Mattessich said in a press release.

Earlier this month, Ocular Therapeutix said that a Phase 3 clinical trial of its ORX-TP eye insert failed to meet the primary endpoint of significant superiority in the reduction of intraocular pressure.

Filed Under: Business/Financial News, Optical/Ophthalmic

IN CASE YOU MISSED IT

  • Dexcom updates CGM receiver recall that led to serious adverse events
  • Abbott reports momentum with Libre CGM business as new dual sensor will ‘accelerate’ growth
  • Johnson & Johnson wins FDA priority review for drug delivery system
  • Glucose monitoring company LifeScan files chapter 11 to reduce debt
  • Medtronic enrolls first patient in study for Onyx liquid embolic system

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS